期刊文献+

人载脂蛋白A5基因的克隆、表达、纯化及多克隆抗体制备

Cloning, Expression, Purification and Polyclonal Antibody Preparation of Human Apolipoprotein A5
下载PDF
导出
摘要 人载脂蛋白A5(ApoA5)是血浆三酰甘油水平的重要决定因素之一,与心血管疾病密切相关,因此获得高纯度的载脂蛋白A5及其抗体具有重要的意义.本文利用PCR技术,从人肝癌细胞系7721的cDNA中扩增出ApoA5基因,并克隆到pThioHisD载体中导入大肠杆菌Escherichia coli BL21(DE3)中进行表达.经优化条件,发酵得到高效表达的融合蛋白.利用融合蛋白上的一段组氨酸序列,用镍离子亲和柱进行纯化,得到纯度大于95%的融合蛋白.使用纯化蛋白免疫新西兰大耳兔,得到多克隆抗体,Western印迹结果显示此多克隆抗体能与ApoA5特异性结合. Apolipoprotein A5 (ApoA5) gene has been shown to play an important role in determining plasma triglyceride concentrations in humans, and is a major independent risk factor of cardiovascular disease. It is important to obtain the purified ApoA5 and antiserum. In this paper, full-length ApoA5 gene was amplified from human hepatoma cell line 7721 eDNA, and cloned into expression plasmid pThioHisD named as pTh-ApoA5. The pTh-ApoA5 was introduced into Escherichia coli BL21 (DE3). After optimizing its fermentation condition, recombinant ApoA5 was highly expressed. The recombinant ApoA5 protein that contained a 6-His sequence was separated by Ni^2+ affinity column and the purity of recombinant ApoA5 was more than 95%. The purified recombinant ApoA5 protein was employed for immunizing rabbits and the antiserum was obtained. Western blot showed that the antibody was specific. Fig 6, Ref28
出处 《应用与环境生物学报》 CAS CSCD 北大核心 2009年第1期95-99,共5页 Chinese Journal of Applied and Environmental Biology
关键词 载脂蛋白A5 原核表达 发酵 纯化 抗体 apolipoprotein A5 prokaryotic expression fermentation purification antibody
  • 相关文献

参考文献28

  • 1Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science, 2001, 294 (5540): 169-173
  • 2van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, Chamuleau RA. Apolipoprotein A-V: A novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem, 2001, 276 (48): 44512-44520
  • 3Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem, 2005, 51 (2): 351-359
  • 4van der Vliet HN, Schaap FG, Levels JH, Ottenhoff R, Looije N, Wesseling JG, Groen AK, Chamuleau RA. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun, 2002, 295 (5): 1156-1159
  • 5van Dijk KW, Rensen PC, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: Synergistic actors in triglyceride metabolism? Curr Opin Lipidol, 2004, 15 (3): 239-246
  • 6Aouizerat BE, Kulkarni M, Heilbron D, Drown D, Raskin S, Pullinger CR, Malloy MJ, Kane JP. Genetic analysis of a polymorphism in the human apoA-V gene: Effect on plasma lipids. J Lipid Res, 2003, 44 (6): 1167-1173
  • 7Frunchart-Najib J, Bauge E, Niculescu LS, Pham T, Thomas B, Rommens C, Majd Z, Brewer B, Pennacchio LA, Fruchart JC. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun, 2004, 319 (2): 397-404
  • 8Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, Havekes LM, Groen AK, van Dijk KW. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem, 2004, 279 (27): 27941-27947
  • 9Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem, 2005, 280 (22): 21553-21560
  • 10Marcais C, Verges B, Charrière S, Pruneta V, Merlin M, Billon S, Perrot L, Drai J, Sassolas A, Pennacchio LA, Frunchart-Najib J, Fruchart JC, Durlach V, Moulin P. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest, 2005, 115 (10): 2862-2869

二级参考文献13

  • 1Pennacchio LA,Olivier M,Hubacek JA,et al.An Apolipoprotein influencing TG in humans and mice revealed by comparative sequencing[J].Science,2001,294:169-173.
  • 2Vn der Vliet HN,Schaap FG,Levels JH,et al.Adenoviral overexpression of apolipoprotein AV reduces serum levels of triglycerides and cholesterol in mice[J].Biochem Biophys Res Commun,2002,295:1156-1159.
  • 3Pennacchio LA,Rubin EM.Apolipoprotein A5,a newly identified gene that affects plasma triglyceride levels in humans and mice review[J].Arterioscler Thromb Vasc Biol,2003,23:529-534.
  • 4Beckstead JA,Oda MN,Martin DD,et al.Structure-function studies of human apolipoprotein A-V:a regulator of plasma lipid homostasis[J].Biochemistry,2003,42:9416-9423.
  • 5Weinberg RB,Cook VR,Berkstead JA,et al.Structure and interfacial properties of human apolipoprotein A-V[J].J Biol Chem,2003,278:34438-34444.
  • 6Talmud PJ,Hawe E,Martin S,et al.Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides[J].Hum Mol Genet,2002,11:3039-3046.
  • 7Baroukh N,Bauge E,Akiyama J,et al.Analysis of apolipoprotein A5,C3,and plasma triglyceride concentrations in genetically engineered mice[J].Arterioscler Thromb Vasc Biol,2004,7:1297-1302.
  • 8Van der Vliet HN,Sammels MG,Leegwater AC,et al.Apolipoprotein AV:A novel apolipoprotein associated with an early phase of liver regeneration[J].J Biol Chem,2001,276:44512-44520.
  • 9Ishihara M,Kujiraoka T,Iwasaki T,et al.A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration[J].Journal of Lipid Research,2005,46:2015-2022.
  • 10O'Brien PJ,Alborn WE,Sloan JH,et al.The novel apolipoprotein A5 is present in human serum,is associated with VLDL,HDL,and chylomicrons,and circulates at very low concentrations compared with other apolipoproteins[J].Clin Chem,2005,51:351-359.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部